Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marion Merrell Dow's Cardizem Injectable approved

Executive Summary

Calcium channel blocker will be launched before the end of November. Cardizem Injectable (diltiazem hydrochloride) is approved for atrial fibrillation or atrial flutter and paroxysmal supraventricular tachycardia. The contraindications and warnings are generally similar to those associated with Cardizem tablets; there are additional contraindications for Cardizem Injectable in patients with an accessory bypass tract, in patients who recently received intravenous beta blockers, and for patients with ventricular tachycardia. The product is approved in 25 mg/5 ml and 50 mg/10 ml doses....
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019910

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel